Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gattex sales chugging along for NPS in 2Q

This article was originally published in Scrip

Executive Summary

NPS Pharmaceuticals has all of its trains running on schedule with Gattex (teduglutide) on track to beat previous estimates by the end of the year, preparations for ex-US sales under way, and plans for a Natpara biologics license application (BLA) filing in the US before the end of 2013.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022398

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel